Scott Struthers, Crinetics CEO
March 19, 2024 07:14 AM EDT
R&D

Cri­net­ics re­ports sec­ond PhI­II win for acromegaly drug, eyes 2025 launch

Katherine Lewin

News Reporter

Cri­net­ics’ sec­ond Phase III tri­al in­ves­ti­gat­ing its drug pal­tuso­tine in a rare hor­mon­al dis­or­der read out topline da­ta on Tues­day, with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times